Search
forResearch 10 of 475
- Outcome Measures in Cutaneous Autoimmune Disease: Dermatomyositis and Lupus Erythematosus
- 570 Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis
- Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures
- Skin
- DP10 Scalp disease in dermatomyositis
- Skin involvement in systemic lupus erythematosus: a review article
- THE IMPACT OF HOMOCYSTEINE IN LUPUS ERYTHEMATOSUS: A LINK OF INFLAMMATION, SKIN AND CARDIOVASCULAR RISK
- Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Development and Validation of a Quality of Life Measurement for Chronic Skin Disorders in French: VQ-Dermato
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →